Myeloma Drug Shows Promise, CVS Backs Obesity Treatments, Kenya Ebola Quarantine Raises Concerns

The health sector sees developments with a new drug by Bristol Myers delaying myeloma progression, CVS renewing coverage for Eli Lilly's obesity treatments, and controversy over a U.S. Ebola quarantine facility in Kenya. The FDA scrutinizes Dabur India for lapses, while Massachusetts sues UnitedHealth for Medicaid fraud.

Bristol Myers Squibb's innovative oral drug mezigdomide is making waves in the medical community. In a late-stage trial, the drug effectively delayed the progression of multiple myeloma in patients unresponsive to other treatments, cutting the risk of disease progression or death by 52%.

CVS Health reinstated coverage for Eli Lilly's obesity drug Zepbound along with its newly approved obesity pill, Foundayo. This decision comes after negotiations regarding pricing with competing drugmaker Novo Nordisk, highlighting the strategic battles within the pharmaceutical industry.

In Kenya, a U.S. plan to establish an Ebola quarantine facility met judicial roadblocks, questioning its potential public health risks. The suspension reflects ongoing global concerns about Ebola's spread and the measures being undertaken to control it.